A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold.

"Declarations Ethics approval and consent to participate: This study was conducted in compliance with the protocol and in accordance with Good Clinical Practices Medicines and Healthcare products Regulatory Agency regulations, and all applicable local and state regulations. Signature of the eIC was required and obtained from all participants before any study-related activities. The eIC was reviewed by West Midlands, Edgbaston, Research Ethics Committee, Manchester, UK. IRAS project ID 1006069, REC:22/WM/0177. Approved by West Midlands – Edgbaston Research Ethics Committee 25 October 2022.Consent for publication: Consent for publication was provided by participants through the eIC form.Author contributions:Martina Hagen: Conceptualization; Formal analysis; Writing – review & editing.Kim Clark: Methodology; Writing – review & editing.Pranab Kalita: Conceptualization; Writing – review & editing.Gessica Serra: Methodology; Writing – review & editing.Edwin Sanchez: Formal analysis; Writing – review & editing.Gabor Varbiro: Formal analysis; Methodology; Writing – review & editing.Mathieu M. Albasser: Formal analysis; Writing – review & editing.Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by Haleon.Competing interests: All authors are employees of Haleon.Availability of data and materials: Anonymized individual participant data and study documents can be requested for further research from https://haleon-study-register.idea-point.com. Clinical trial details can be found on Study Record | Beta ClinicalTrials.gov. Competing interests: All authors are employees of Haleon."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by Haleon."